在一般医学期刊上发表的受控试验报告中的讨论部分
Mike Clarke1, Phil Alderson, Iain Chalmers
1UK Cochrane Centre, National Health Service Research and Development Programme, Summertown Pavilion, Middle Way, Oxford OX2 7LG, England. mclarke@cochrane.co.uk
JAMA
|June 1, 2002
概括
解释受控试验结果需要类似研究的背景. 2001年的一项研究发现,主要医学期刊的报道仍然未能与现有的系统性审查一起讨论新发现,自1997年以来没有进展.
科学领域:
- 医学研究方法学 医学研究方法学
- 基于证据的医学基于证据的医学.
- 临床试验报告报告
背景情况:
- 解释受控试验结果需要与现有研究联系起来.
- 之前的一项研究在1997年发现了这种上下文化的缺陷.
- 这项研究重新评估了相同的期刊,以评估进展.
研究的目的:
- 评估对照试验报告在多大程度上讨论新的结果,考虑到其他对照试验的证据总和.
- 为了确定在1997年至2001年期间,是否有改善的试验结果上下文化.
主要方法:
- 对33个随机试验报告的讨论部分的分析.
- 在2001年5月份在五个主要的通用医学期刊上发表.
- 结果与1997年5月的类似评估结果进行了比较.
主要成果:
- 只有三个报告讨论了新的研究问题.
- 剩下的30份报告中,没有一个结合了新的试验结果与更新的系统审查.
- 27份报告显示,没有系统的努力将研究结果与先前的证据联系起来.
结论:
- 在1997年至2001年期间,没有观察到任何改善.
- 在一般医学期刊的报道中,在最新的系统性审查的背景下,没有充分讨论新的试验结果.
相关概念视频
Clinical Trials
Clinical trials are prospective experimental studies conducted on humans to determine the safety and efficacy of treatments, drugs, diet methods, and medical devices. Using statistics in clinical trials enables researchers to derive reasonable and accurate conclusions from the collected data, allowing them to make wise decisions in uncertain situations. In medical research, statistical methods are crucial for preventing errors and bias.
There are four phases in a clinical trial. A phase one...
There are four phases in a clinical trial. A phase one...
Clinical Trials: Overview
Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
Pharmacovigilance
Post-marketing surveillance is a critical component of pharmaceutical regulation, often uncovering unanticipated adverse drug reactions (ADRs) once a drug is widely used over an extended period.
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches
Biopharmaceutical studies constitute a vital field aiming to enhance drug delivery methods and refine therapeutic approaches, drawing upon diverse interdisciplinary knowledge. In research methodologies, the choice between controlled and non-controlled studies significantly influences the study's reliability and accuracy.
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast, controlled...
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast, controlled...
Toxicity Testing in Animals
Toxicity tests in animals are grounded on two main assumptions: first, the effects observed in laboratory animals can be extrapolated to humans, especially when adjusted for body surface area; second, high-dose exposure in animals is essential to identify potential human hazards from lower doses. This is based on the quantal dose-response concept, which faces the challenge of extrapolating results from relatively few test animals to much larger human populations. For example, a 0.01% incidence...
Hazard Ratio
The hazard ratio (HR) is a widely used measure in clinical trials to compare the risk of events, such as death or disease recurrence, between two groups over time. It reflects the ratio of hazard rates—the instantaneous risk of the event occurring—between a treatment group and a control group. This measure provides valuable insights into the relative effectiveness of a treatment by assessing how the risk of an event differs between the two groups.
For example, in a clinical trial evaluating a...
For example, in a clinical trial evaluating a...


